ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

ImageneBio IncNASDAQ: IMA

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was $0.

Context

  • Capital expenditures amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Capital expenditures increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Capital Expenditures vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
IMA Competitors
Capital Expenditures for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STTKShattuck Labs, Inc.LTM Mar 2026$10.42M USD-12.9%-81.7%1042.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$2.32M USD+104.2%-25.7%—
STROSutro Biopharma, Inc.LTM Mar 2026$532K USD-86.1%-40.0%0.5%
CNTBConnect Biopharma Holdings LimitedFY2025$434K USD-42.1%-53.4%678.1%
KLRSKalaris Therapeutics IncLTM Mar 2026$200K USD———
IFRXInflaRx N.V.LTM Mar 2026€114.87K EUR+178.5%-11.9%391.6%
CNTXContext Therapeutics Inc.LTM Mar 2026$37.26K USD-9.7%-60.2%—
IMAImageneBio IncLTM Mar 2026$0 USD———
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD+100.0%—0.0%
Peer median (excluding IMA) —-9.7%-46.7%391.6%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(34.12M)(68.77M)(68.17M)(49.23M)(52.4M)
Depreciation & Amortization544K751K1.02M490K328K
Deferred Income Tax00000
Stock-Based Compensation5.18M7.53M05.3M15.39M
Change in Working Capital(33.03M)(15.14M)(21.67M)(3.98M)(19.19M)
Accounts Receivables361K(291K)000
Inventory00000
Accounts Payables00(2.87M)(1.17M)(2.82M)
Other Working Capital(33.39M)(14.85M)(18.8M)(2.81M)(16.37M)
Other Non-Cash Items1.17M1.52M9.07M1.42M8.02M
Operating Cash Flow(60.25M)(74.11M)(79.74M)(46M)(47.84M)
Capital Expenditures(1.76M)(1.43M)(414K)00
Acquisitions (Net)0000(5.22M)
Purchases of Investments0(216.34M)(90.05M)(88.3M)(10.4M)
Sales of Investments0118.49M154.61M60.46M9.8M
Other Investing Activities000(7.07M)0
Investing Cash Flow(1.76M)(99.28M)64.14M(34.9M)(5.81M)
Debt Repayment000015M
Common Stock Issued131.3M037.56M065.84M
Common Stock Repurchased00(663K)00
Dividends Paid00000
Other Financing Activities582K1.1M39.09M054.63M
Financing Cash Flow131.74M1.1M75.98M0135.47M
Effect of Forex Changes00(406K)0604K
Net Change in Cash69.73M(172.3M)59.98M(80.91M)82.41M
Free Cash Flow(62.01M)(75.54M)(80.16M)(46M)(47.84M)

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.